Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-661-5 | CAS number: 109-28-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted in accordance with OECD guideline 407 and GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- N-[3-(dimethylamino)propyl]oleamide
- EC Number:
- 203-661-5
- EC Name:
- N-[3-(dimethylamino)propyl]oleamide
- Cas Number:
- 109-28-4
- Molecular formula:
- C23H46N2O
- IUPAC Name:
- (9Z)-N-[3-(dimethylamino)propyl]octadec-9-enamide
- Test material form:
- other: liquid
- Details on test material:
- Color: reddish
Batch: R401/57
Purity: 78.2 area-%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Supplier: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, 97633 Sulzfeld
Age at beginning of administration period: 42+/-1 days
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- drinking water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analyses of the test-substance preparations were carried out as a separate study at the test facility GKA Competence Center Analytics, BASF SE, Ludwigshafen, Germany under the responsibility of the Study Director of this facility. The study was carried out in compliance with the Principles of GLP. The stability of the test substance in drinking water for a period of 7 days was proven before the start of the administration period.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
10, 50 and 150 mg/kg body weight
Basis:
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Rationale for selection of doses: In a pre-test, the test substance was administered to Wistar rats at dose levels of 1000 and 300 mg/kg body weight/day by gavage for a period of 2 weeks. Several severe clinical findings were observed even at 300 mg/kg including premature death. Therefore, 150 mg/kg body weight/day was selected as the highest dose in the present study.
Examinations
- Observations and examinations performed and frequency:
- - Mortality: twice daily on working days, once daily on Saturdays, Sundays and public holidays
- Clinical observations: daily before and after administration
- Detailed clinical observations: performed in all animals prior to the administration period and thereafter at weekly intervals. Parameters examined: abnormal behavior during “handling”, fur, skin, posture, salivation, respiration, activity/arousal level, tremors, convulsions, abnormal movements, impairment of gait, lacrimation, palpebral closure, exophthalmus, feces (appearance/consistency), urine, pupil size.
- Food consumption: determined weekly over a period of 1 day
- Water consumption: determined weekly over a period of 4 days
- Body weight: determined before start of administration period, at start of administration period and weekly thereafter
- Food efficiency: calculated based upon individual values for body weight and food consumption
- Functional observational battery: performed in all animals at the end of the administration period
- Motor activity assessment: performed in all animals towards the end of the administration period
- Ophthalmoscopy: performed in all animals prior to the start of the administration period and in the control and high dose animals on day 28 - Sacrifice and pathology:
- Parameters examined in clinical pathology:
- Hematology: Leukocyte count, Erythrocyte count, Hemoglobin, Hematocrit, Mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, differential blood count, reticulocytes, prothrombin time
- Clinical chemistry: ALT, AST, ALP, GGT, sodium, potassium, chloride, inorganic phsophate, calcium, urea, creatinine, glucose, total bilirubin, total protein, albumin, globulins, triglycerides, cholesterol, magnesium
- Urinalysis: pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, specific gravity, sedinment, color/turbidity, volume
Organs/parameters examined in pathology:
- Weights: anestzetized animals, liver, kidneys, adrenal glands, testes, epididymides, ovaries, uterus, spleen, brain, heart, thymus, thyroid glands
- Preserved organs/tissues: all gross lesions, brain, pituitary gland, thyroid glands, parathyroid glands, thymus, esophagus, salivary glands (mandibular gland, sublingual gland), trachea, lungs, pharynx, larynx, nose (nasal cavity), aorta, heart, liver, pancreas, spleen, kidneys, adrenal glands, testes, ovaries with oviducts, uterus, vagina, epididymides, prostate, seminal vesicles, stomach (fore- and glandular stomach), duodenum, jejunum, ileum, cecum, colon, rectum, urinary bladder, lymph nodes (mesenteric and axillary lymph node), sciatic nerve, bone marrow (femur), eyes, extraorbital lacrimal glands, skin, female mammary glands, skin, female mammary gland, spinal cord (cervical, thoracic and lumbar cord), sternum with marrow, femur with knee joint, skeletal muscle.
- Histopathology: all gross lesions, salivary glands (mandibular and sublingual), brain, pituitary gland, eyes, esophagus, thyroid glands, parathyroid glands, thymus, trachea, lungs, aorta, heart, liver, pancreas, spleen, kidneys, adrenal glands, testes, ovaries with oviducts, uterus, vagina, female mammary gland, epididymides, prostate, seminal vesicles, stomach (fore- and glandular stomach), duodenum, jejunum (with Peyer's plaques), ileum, cecum, colon, rectum, urinary bladder, lymph nodes (mesenteric and axillary lymph node), sciatic nerve, skin, bone marrow (femur), spinal cord (cervical, thoracic and lumbar cord) - Statistics:
- Means and standard deviations of each test group were calculated for the following parameters:
- Body weight, body weight change (comparison of each group with the control group was performed using a two-sided DUNNETT's test for the hypothesis of equal means)
- Feces, rearing, grip strength length forelimbs, grip strength length hindlimbs, footsplay test, motor activity (Non-parametric oneway analysis using a two-sided KRUSKAL-WALLIS test. If the resulting p-value was equal or less than 0.05, a pairwise comparison of each dose group with the control group was performed using a two-sided Wilcoxon-test for the equal medians.)
Statistics of pathology:
Weight parameters were analyzed with a non-parametric one-way analysis using KRUSKAL-WALLIS test (two-sided). If the resulting p-value was equal or less than 0.05, a pair wise comparison of each dose group with the control group was performed using the WILCOXON test for the hypothesis of equal medians.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- No premature mortality occured. Salivation was observed predominantly after treatment in all animals of either sex of dose group 3 (150 mg/kg bw/d) on few days between study day 11 and 28. Besides, respiration sounds were observed predominantly after treatment in 3 male and 4 female animals of dose group 3 (150 mg/kg bw/d) on several days between study day 7 and 28. These findings were assessed as adverse and related to the test article.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- No premature mortality occured. Salivation was observed predominantly after treatment in all animals of either sex of dose group 3 (150 mg/kg bw/d) on few days between study day 11 and 28. Besides, respiration sounds were observed predominantly after treatment in 3 male and 4 female animals of dose group 3 (150 mg/kg bw/d) on several days between study day 7 and 28. These findings were assessed as adverse and related to the test article.
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- BODY WEIGHT AND WEIGHT GAIN:
Body weight was significantly increased (+10.6%) in male animals of the 10 mg/kg bw/d dose group on day 28. This single occurence was without any correlative to food consumption or other clinical oarameters. It was therefore considered as not treatment-related.
HAEMATOLOGY:
Some deviations in the differential blood cell counts without any change of the total white blood cell count were found in the female rats of the 10 and the 150 mg/kg bw/d dose groups: an increase of the absolute and relative neutrophil counts as well as relative basophil counts and a decrease of the relative lymphocyte counts. The statistically significant changes in the dosed rats were due to low neutrophil and basophil and high lymphocyte counts in the control rats of this study. The deviations were not dose-dependent. All values were within, or very slightly out of the borders of the historical control ranges.
CLINICAL CHEMISTRY:
In the male rats of the 150 mg/kg bw/d dose group, the calcium concentration was increased compared to the controls. This was the only deviated clinical chemistry parameter in these animals. Therefore it was regarded as non adverse, although it cannot be excluded that this change was treatment related.
URINALYSIS:
In the female rats of the 50 mg/kg bw/d dose group, the specific gravity of the urine was statistically significantly decreased. This change was not dose-dependent or accompanied by any other deviations in the urine. It was therefore considered not adverse.
NEUROBEHAVIOUR
ORGAN WEIGHTS:
Kidney weights were significantly changed in the female rats of the 10 mg/kg bw/d dose group as compared to the control group. As not significant deviations from the control animals were observed in the higher dose groups, this finding was considered not treatment-related.
The relative brain weights were changed in all treated female rats as compared to the control group. No dose-response relationship or histopathological correlate ws observed, and therefore this finding was considered to be not treatment-related.
GROSS PATHOLOGY
All gross lesions occured singly or were biologically equally distributed between control and treatment groups.
HISTOPATHOLOGY:
All findings noted were either single observations or they were biologically equally distributed between control and treatment group. All of them are considered to be incidental or spontaneous in origin and without any relation to treatment.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- > 50 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: Salivation and respiration sounds in male and female animals in the 150 mg/kg dose group
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The oral administration of 3-Dimethyl-aminopropyl-ölsäureamide by gavage over a period of 28 days at dose levels of 10, 50 and 150 mg/kg bw/day caused slight toxicity in animals in the high dose group of either sex. Therefore, the NOAEL under the conditions of the present study was 50 mg/kg body weight/day in both male and female rats.
- Executive summary:
3-Dimethyl-aminopropyl-ölsäureamide was administered to groups of 5 male and 5 female Wistar rats at doses of 10, 50 and 150 mg/kg bw/day with a control group concurrently treated with vehicle (drinking water) over a period of 28 days by gavage. Food and water consumption and body weight were determined weekly. The animals were examined for signs of toxicity and mortality at least once a day. Additionally, further clinical examinations were carried out daily. Detailed clinical examinations in an open field were conducted prior to the start of the administration period and weekly thereafter. Ophthalmological examinations were conducted before the beginning and towards the end of the administration period. Additionally, a functional observational battery (FOB) as well as measurement of motor activity was carried out at the end of the study. Clinicochemical and hematological examinations as well as urinalyses were performed towards the end of the administration period. All animals were assessed by gross pathology, followed by histopathological examinations.
No substance-related adverse findings were obtained in the 10 and the 50 mg/kg bw/day dose groups. In the 150 mg/kg bw/day dose group, salivation was observed after treatment in all male and female animals on few days between study day 11 and 28. Furthermore, Respiration sounds were observed after treatment in 3 male and 4 female rats on several days between study day 7 and 28. Based on the findings in the high dose group, a NOAEL of 50 mg/kg bw/day was drived for both male and female rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.